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Abstract
Background: Chronic pain patients have increased peripheral blood mononuclear cell Interkeukin-1b production following
TLR2 and TLR4 simulation. Here we have used a human-to-rat and rat-to-human approach to further investigate whether
peripheral blood immune responses to TLR agonists might be suitable for development as possible systems biomarkers of
chronic pain in humans.
Methods and Results: Study 1: using a graded model of chronic constriction injury in rats, behavioral allodynia was assessed
followed by in vitro quantification of TLR2 and TLR4 agonist-induced stimulation of IL-1b release by PBMCs and spinal cord
tissues (n = 42; 6 rats per group). Statistical models were subsequently developed using the IL-1b responses, which
distinguished the pain/no pain states and predicted the degree of allodynia. Study 2: the rat-derived statistical models were
tested to assess their predictive utility in determining the pain status of a published human cohort that consists of a
heterogeneous clinical pain population (n = 19) and a pain-free population (n = 11). The predictive ability of one of the rat
models was able to distinguish pain patients from controls with a ROC AUC of 0.94. The rat model was used to predict the
presence of pain in a new chronic pain cohort and was able to accurately predict the presence of pain in 28 out of the 34
chronic pain participants.
Conclusions: These clinical findings confirm our previous discoveries of the involvement of the peripheral immune system
in chronic pain. Given that these findings are reflected in the prospective graded rat data, it suggests that the TLR response
from peripheral blood and spinal cord were related to pain and these clinical findings do indeed act as system biomarkers
for the chronic pain state. Hence, they provide additional impetus to the neuroimmune interaction to be a drug target for
chronic pain.
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Introduction
Pain as defined by the International Association for the Study of
Pain is an unpleasant sensory and emotional experience associated
with actual or potential tissue damage, or described in terms of
such damage. Pain is a subjective experience, and hence it is
conventionally assessed by patient reports, sometimes with added
rating scales. Preclinical animal pain research cannot use such
measures, but instead relies on behavioral responses to infer the
pain experience. There is a large failure rate in clinical translation
of therapies that are efficacious in standard preclinical animal
studies, possibly in part because of these different assessments [1].
Biomarkers that reflect pain biology and which could be used in
both preclinical animal and clinical human studies have the
potential for improving translational success in pain research.
Additionally, practical human pain biomarkers have potential uses
in enriching clinical trial populations, assisting in the selection of
patient treatment and monitoring treatment efficacy [2].
Development of pain biomarkers is problematic because of
difficulty in accessing the central nervous system (CNS) where the
chronic pain pathology likely resides. Although neuroimaging has
emerged as a potential biomarker for chronic pain, by providing
‘‘pain signatures’’ of the brain [3–6], there are several limitations
to its usage [7]. Instead, we have sought evidence that peripheral
tissues reflect functional changes of the CNS and hence have the
potential to be accessible human pain biomarkers.
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Over the past 20 years substantial evidence has accumulated
indicating the involvement of non-neuronal cells playing a pivotal
role in chronic pain. In particular, the immunocompetent cells of
the CNS, glia, respond to pain signals releasing additional pro-
nociceptive proinflammatory mediators that in turn sensitize
neighboring neurons and glia facilitating the heightened pain state
[8–12]. Interestingly, this research points to attenuating proin-
flammatory glial activation is a promising new target for the
treatment of neuropathic pain, as drugs that attenuate pro-
inflammatory glial activation results in a reduction in allodynia
[13–16].
A key mediator in the initiation of proinflammatory glial
reactivity associated with chronic pain is Toll Like Receptors
(TLRs). TLRs are an innate immune receptor family that
recognize danger-associated molecular patterns (DAMP) and
pathogen-associated molecular patterns [17]. Activation of TLRs
causes the production of pro-inflammatory mediators such as pro-
inflammatory cytokines (such as IL-1b) [9]. It is clear from
preclinical models that glia assume a proinflammatory reactive
state following activation by TLRs and that blockade of glial TLRs
significantly reduces experimentally induced neuropathic pain
[18–20]. Interestingly, we have recently demonstrated that in
chronic pain patients, peripheral blood mononuclear cells
(PBMCs) also have increased TLR2 and TLR4 responsiveness
compared with pain-free participants [21], suggesting that this
could be a potential pain biomarker.
However, given the cross-sectional nature of the human data
which hinders cause-and-effect analysis, we have sought whether
similar findings occur in a prospective graded animal model to
support that interpretation that this biomarkers lie on the causal
pathway rather than being bystander effects. Additionally we have
sought whether a biomarker panel based on TLR-induced IL-1b
production by PBMCs can distinguish pain from non-pain states in
two separate clinical pain populations (medication overuse
headache and sciatica) to explore potential clinical utility.
Materials and Methods
Study 1: Graded Chronic Constriction Injury Surgery and
Sample Preparation
Animals. Pathogen-free adult male Sprague–Dawley rats
(300–350 g; University of Adelaide, Laboratory Animal Services,
Waite Campus, Urrbrae, Australia) were used in all experiments.
Rats were housed in a temperature-controlled (18–21uC) and
light-controlled (12 h light/dark cycle; lights on at 07:00 h) rooms
with standard rodent chow and water available ad libitum. Animals
were habituated to the holding facility for 1 week prior to
experimentation. All procedures were approved by the Animal
Ethics Committee of the University of Adelaide and were
conducted in accordance with the NHMRC Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes.
Surgery. A graded neuropathic pain model, the ‘‘Grace
model’’ was used [22]. Surgery was conducted under isofluorane
(3% oxygen) anaesthesia. Briefly, the sciatic nerve was exposed at
the mid-thigh level of the left leg as previously described [23].
Between zero and 4 sterile chromic gut sutures (cuticular 4–0
chromic gut, FS-2; Ethicon, Somerville, NJ, USA) were loosely
tied around the gently isolated sciatic nerve to produce varying
degrees of allodynia. Once the superficial muscle overlying the
nerve was sutured, the animals had varying numbers of chromic
gut suture (equivalent length) placed in the subcutaneous space.
For sham treatment, the sciatic nerve was identically exposed and
isolated but not tied. Animals were monitored postoperative (PO)
until fully ambulatory prior to the return of their cage and checked
daily for signs of infection. No such cases occurred in this study.
Experimental groups and design. Experimental groups
used in the Grace model were also selected in this study. The
sciatic nerve was loosely ligated with chromic gut sutures, with the
number of perineural sutures indicated by the designation N0, N1,
N2 or N4. Additional pieces of chromic gut designated S4, S3, S2
or S0 respectively were also placed in the subcutaneous space, to
keep the total number of ligatures to 4, in order to keep the non-
specific immunological stimulus constant between the groups. This
model has been shown to produce graded neuropathic pain in
relation to the number of ligatures around the nerve. Two
additional groups (N1S0 and N2S0) with only ligatures to the
sciatic nerve were also introduced to examine only neuronal
insults. For the sham control the nerve was isolated but there was
no exposure to chromic gut. N0S4 was a control group for the
presence of chromic gut. The experimental groups (6 rats/group)
were N0S0 (sham control), N0S4, N1S0, N1S3, N2S0, N2S2 and
N4S0.
Behavioral testing: von frey test. Rats were habituated for
at least three sessions (60 min) to the test environment prior to von
Frey testing. Testing was performed blinded with respect to the
experimental group. The von Frey test was performed within the
sciatic innervation area of the hind paw. Assessments were at
baseline, PO day 3, 7, 10 and day of cull and the development of
allodynia was assessed. Animals were followed to at least PO day
18 to ensure the neuropathic pain was well established. A
logarithmic series of ten calibrated Semmes-Weinstein monofila-
ments (von Frey hairs; Stoelting, Wood Dale, IL, USA) were
applied randomly to the left hind paw to determine the stimulus
intensity threshold stiffness required to elicit a paw withdrawal
response. Log10 (milligrams610) hair stiffness ranged from 3.61
(0.407 g) to 5.18 (15.136 g). The behavioral responses were used
to calculate the 50% paw withdrawal threshold (absolute
threshold), by fitting a Gaussian integral psychometric function
using a maximum-likelihood fitting method using the program
PsychoFit [24]. This fitting method allows parametric analyses that
otherwise would not be appropriate.
Peripheral blood and spinal cord collection. On the day
of cull (at least PO 18 day), rats were anesthetized with sodium
pentobarbital and blood (approximately 7 mL) was collected via
cardiac puncture into tubes containing EDTA. The rat was then
transcardially perfused with 15 ml of chilled 0.9% isotonic saline
and the lumbar spinal cord was quickly removed and dissected
into 3 equal lengths. The isolated spinal cord was incubated for
20 h at 37uC, 5% CO2 in a humidified environment (Thermoline
Scientific, Australia). Added to the incubation medium were
either: 10 mg/mL of TLR2 agonist synthetic triacylated lipopro-
tein (Pam3CSK4) or 10 mg/mL of TLR4 agonist lipopolysaccha-
ride (LPS) from Sigma-Aldrich (Castle Hill, NSW, Australia) or
RPMI medium only (control).
Stimulation of rat peripheral blood mononuclear cells
(PBMCs) and plasma collection. PBMCs were isolated using
Optiprep Sigma-Aldrich (Castle Hill, NSW, Australia) as directed
by the manufacturer using the mixer flotation method. Plasma was
also collected and stored at 270uC until the ELISA. Isolated cells
were diluted to 16106 cells?ml21 in enriched RPMI 1640 (10%
fetal calf serum and 1% penicillin) and plated into 96 well plates
(Nunc, Roskilde, Denmark) (100 ml per well). When insufficient
cells were obtained (5 rats), data were adjusted to 16106 cells (by
multiplication of the factor to obtain a response for IL-1b 16106
cells). A range of concentrations was added into the wells, TLR2
agonist (Pam3CSK4) from 10 ng?ml
21 to 1 mg?ml21 and TLR4
agonist (LPS) from 10 ng?ml21 to 10 mg?ml21. Control wells
TLR Responsiveness as Potential Pain Biomarker
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minus the TLR agonist were also included. Plates were incubated
for 20 h at 37uC, 5% CO2 in a humidified environment
(Thermoline Scientific, Australia).
Spinal cord sample preparation. Briefly, after 20 h of
incubation the supernatant of the spinal cord was stored at 280uC
until assay. The spinal cord sections were removed and sonicated
using a Labsonic 1510 probe sonicator (B. BRAUN, Melsungen,
Germany) in ice-cold extraction buffer containing Iscove’s
medium with 5% FCS and a cocktail enzyme inhibitor (including:
100 mM amino-n-caproic acid, 10 mM EDTA, 5 mM benzami-
dine-HCL, and 0.2 mM phenylmethylsulfonyl fluoride) all ob-
tained from Sigma-Aldrich (Castle Hill, NSW, Australia). Soni-
cated samples were centrifuged with the supernatant and stored at
270uC until assay.
Study 2: Chronic Pain and Pain-free Participants
Study participants. The data presented here was obtained
from 1 published study [21] and 2 unpublished clinical studies.
Ethical approval was obtained from the Human Research Ethics
Committee of the Royal Adelaide Hospital, Adelaide, South
Australia. All studies were conducted at the Pain and Anaesthesia
Research Clinic (PARC), Royal Adelaide Hospital, Adelaide,
Australia.
All participants gave written informed consent to participate
after a detailed oral explanation of the study. All participants were
paid for their inconvenience upon completion of the study.
Chronic pain patients were recruited from the PARC volunteer
database, by public advertisements and from a pain management
unit. Healthy participants were recruited from the PARC’s healthy
participant database. Sixty-four participants were recruited and
participants were divided into 2 cohorts: published cohort
(consisted of participants from a previous study [21]) and an
expanded cohort.
The published cohort consisted of chronic pain participants and
pain-free participants. Chronic pain participants had to experience
pain at least five days a week and for at least 3 months. The pain-
free participants had no clinically significant chronic pain and
were not taking opioids or other analgesics. The expanded cohort
consisted of mainly unilateral sciatica and medication-overuse
headache participants. Unilateral sciatica participants had to
experience pain at least five days a week and for at least 3 months.
For the medication-overuse headache participants, the inclusion
criteria included regular use for at least 3 months of opioid-
containing analgesics (10$ days per month) headache present on
at least 15 days/month (for at least 2 months), headache developed
or markedly worsened during medication-overuse and primary
indication for analgesics is a headache disorder.
There was no minimum pain score for eligibility. Chronic pain
patients from both cohorts could be taking ongoing opioid therapy
or not on any chronic opioid therapy. For all participants the key
inclusion criteria were the following: aged between 18 and 65
years, be in good general health (other than chronic pain patients)
without clinically significant renal, hepatic, cardiac or other
diseases. Key exclusion criteria were: use of any immunosuppres-
sant drugs (e.g. azathioprine); presence of an active inflammatory
process; a clinically significant infection in the previous 4 weeks; a
positive urine screen for illicit drugs (except for prescribed opioids),
pregnancy and/or lactation, and have a known history of hepatitis
B, C or HIV.
Human blood collection and PBMCs isolation. On the
study day, information on pain history and medication use was
recorded. Twenty-seven ml of blood were collected into tubes
containing EDTA and the same procedure mentioned previously
Figure 1. Overview of the generation of models in post graded CCI rats.
doi:10.1371/journal.pone.0077799.g001
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in ‘‘Stimulation of rat PBMCs and plasma collection’’ was
performed. Sufficient cells were obtained from all participants
and plasma was not collected in humans. A range of concentra-
tions of TLR agonists were added into the wells in triplicate,
Pam3CSK4 from 13 pg?ml21 to 1 mg?ml21 (Sigma) and LPS from
6 pg?ml21 to 10 mg?ml21 (Sigma). Control wells minus the TLR
agonist were also included.
Rat and Human IL-1b Assay
IL-1b level was determined by a commercially available ELISA
(rat IL-1b ELISA; eBioscience, San Diego, CA and for human IL-
1b ELISA; BD Bioscience, Australia). For the rat’s ELISA kit, the
manufacturer’s instructions were modified by extending the
standard curve from 39 pg/mL to 5 pg/mL so that lower
concentration of IL-1b could be detected. The extended standard
curve was accepted for each ELISA when the R-square (goodness
of fit) was above 0.99. For the human’s ELISA kit the IL-1b levels
were determined according to the manufacturer’s instructions. UV
absorbance was quantified on a BMG PolarStar microplate reader
(BMG Labtechnologies, Offenburg, Germany) at 450 nm with
absorbance at 570 nm subtracted. The modified limit of
quantification of 5 pg?ml21 was used for the rat’s ELISA kit and
for the human’s ELISA kit the manufacturer’s limit of quantifi-
cation of 0.8 pg?ml21 was used.
Study 1 Development of Models from Peripheral and
Central Obtained IL-1b Released from Post Graded CCI
Rats
Overview of modeling. The overview of the modeling is
summarize in Figure 1. All the collected outputs from the rat
(presented in Table 1 and 2.) were imported into the statistical
computing environment R (R Development Core Team, 2007). In
order to determine whether models constructed with the collected
output variables allow: (A) categorization of the pain/no pain
states in rats (B) the detection of the allodynia severity in rats (C)
whether in rats, central outputs can be predicted with peripheral
outputs. The generalized linear model (glm) and the R function
stepAIC were used to generate models. StepAIC function [25]
performs stepwise model selection (backward and forward
selection) using the Akaike information criterion (AIC) as a
variable selection criterion. The functions glm and stepAIC are
both found in the Modern Applied Statistics with S (MASS)
package (From the statistical software R; www.r-project.org).
The glm function assesses how much each output variable
contributes to a response; the responses in question were (A) pain,
(B) von Frey score and (C) spinal cord IL-1b output (Figure 1). The
stepAIC function was used to refine the model by identifying
specific output variables that contributed the most to the model
and removed others that added no value to the model.
Grouping of output variables. To further dissect which
output variables were needed to create the best model to predict
the presence and severity of allodynia. The output variables were
divided according to anatomical locations and by stimulations as
outlined in Figure 2. ‘‘Dataset’’ contained all output variables
collected from all anatomical locations and from all stimulations.
Whereas subsets contained specific output variables group from
either specific location (e.g. Central subset only consist output
variables obtained from central region) or from specific stimulation
(e.g. TLR2 subset consist output variables stimulated only with
TLR2 agonists). The 5 subsets were Peripheral, Central, Basal,
TLR2 and TLR4.
To explore the interaction between the effects of nerve alone
and combined suture placement, experimental groups were also
divided into ‘‘Neuronal and subcutaneous’’ (N0S0, N0S4,
N1S3, N2S2 and N4S0) and ‘‘Neuronal’’ (N0S0, N1S0, N2S0
and N4S0) groups. Within the group, the output variables were
further divided into the 5 different subsets as mentioned above.
Best model A selection: To predict the presence of
pain. N0S0 and N0S4 were experimental groups which
considered to have no pain (assigned as 0) because on the day of
cull the behavior score indicated there were no group differences
between N0S0 (sham) and N0S4. The 5 experimental groups
considered to have pain were assigned as 1 and consists of N1S0,
N1S3, N2S0, N2S2 and N4S0 (see Figure 1). The glm function
was used to predict the presence of pain for the following datasets
and subsets from all experimental groups:
N All dataset and the following 5 subsets: Peripheral, Central,
Basal, TLR2 and TLR4
The stepAIC function was performed to select output variables
that contributed significantly to the refined model. Receiver
Operating Characteristic (ROC) curves were generated from the
refined model and the area under the curve was calculated. One-
way ANOVA was used to compare the model generated from the
All dataset with the 5 subsets (see Figure 1).
The same process was repeated with the Neuronal and
subcutaneous and Neuronal only experimental groups and
their corresponding 5 subsets (e.g. Peripheral).
Best model B selection: To predict the severity of
allodynia. The glm function was used to predict the severity
of allodynia (von Frey score at day of cull) and the stepAIC
function was used to identify the refined model for All
experimental groups:
N All dataset and the following 5 subsets: Peripheral, Central,
Basal, TLR2 and TLR4
A Pearson correlation was chosen to determine the relationship
between the actual von Frey score and the data predicted by the
refined model. The adjusted R-square was used as it takes into
account the number of variables introduced to the refined model.
One-way ANOVA was used to compare the model generated
from the All dataset with the 5 subsets (see Figure 2) to determine
which models is a better predictor of the severity of allodynia.
The same process was repeated with the Neuronal and
subcutaneous and Neuronal only experimental groups and
their corresponding 5 subsets (e.g. Peripheral).
Best model C selection: Prediction of IL-1b central output
by models generated from peripheral outputs. The glm
function and the stepAIC function were used to generate the
refined model to predict the basal spinal cord supernatant IL-1b
with output variables obtained from the Peripheral subset (from
All and for Neuronal and subcutaneous experimental
groups). A Pearson correlation was used to determine the
relationship between the predicted values (from the refined model)
with the actual IL-1b released from the basal spinal cord
supernatant. The adjusted R-square was used and the same
procedure was used to generate the model to predict the IL-1b
released from the lumbar spinal cord supernatant (post TLR2 and
TLR4) and the lumbar spinal cord (basal, post TLR2 and TLR4)
response.
TLR Responsiveness as Potential Pain Biomarker
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Study 2 Development of Model D to Predict the Presence
of Pain in Humans (Chronic Pain and Pain-free
Participants) and Compare Models Generated from Study
1
The overview of the modeling is summarized in Figure 3. The
chronic pain patients in the published cohort [21] were the group
considered to have pain therefore assigned as 1. The pain-free
participants were considered to have no pain hence assigned as 0.
The ‘‘Model human’’ was the refined model constructed from the
collected outputs (Table 3) from the ‘‘published cohort’’ [21] with
the use of the glm and stepAIC function.
Comparison of different models developed from rats and
humans. ‘‘Model rat to human’’ used the output variables
selected by the Peripheral subset obtained from rats (from all
experimental groups) and applied to the clinical data obtained
from the ‘‘published cohort’’ [21] (listed in Table 3). A ROC curve
was generated from both models and the area under the curve was
calculated. One-way ANOVA was used to compare the models
Table 1. Summary of variables collected from rats post CCI in the periphery region.
Variables P- value
Peripheral (PBMCs) N0S0 N0S4 N1S3 N2S2 N4S0 N1S0 N2S0
Non-stimulated Plasma IL-1b (pg/mL) 1.760.4 2.760.7 1.460.4 3.360.3 1065.3 460.3 5.561.7 0.03
Cell count
(‘6 cells/mL)
3.461.8* 7.461.5 9.262.8*# 3.560.8 5.961 1.860. 7# 5.662.1 0.004
Cells IL-1b (pg/mL) 6.361.7 4.960.6 5.761 7.562.8 4.660.4 4.861.1 4.760.4 1
Pam3CSK4stimulated (TLR2)
IL-1b (pg/mL)
Minimum 2.360.7 3.160.9 2.560.4 3.660.5 2.260.7 3.760.7 3.860.7 0.5
Maximum 8.461.8 13.964 14.563.2 12.763.5 9.561.4 8.662.4 10.562.3 0.7
Slope 20.660.5 22.161.7 1.161.7 0.360.9 20.160.8 20.0960.6 21.961.4 0.02
Intercept 5.461.1 8.762.6 5.860.6 761 5.660.5 5.760.9 6.461.04 0.4
LPS stimulated (TLR4) IL-1b
(pg/mL)
Minimum 1263.3 14.566.1 26.4610.2 23.667.2 1663.1 12.864.7 1667.3 0.2
Maximum 24.566.8 31.4610.6 70.5639.7 65.4619.1 27.765.8 41.5619 45.3625.3 0.7
Slope 3.761.8 2.862 217.4617.5 11.867.5 3.261.9 9.264.8 8.969 0.5
Intercept 13.763 20.166.8 60.7635.8 28.667.7 18.263.1 16.366.1 18.965.6 0.8
Control Neuronal and Subcutaneous Neuronal
Experimental Groups
Data are presented as mean 6 SEM. Peripheral blood mononuclear cells (PBMCs) were isolated from 41 rats and stimulated with LPS (10 ng?ml21 to 10 mg?ml21) and
with Pam3CSK4 (from 10 ng?ml21 to 1 mg?ml21) for 20 h. No PBMCs could be obtained from 1 rat in N2S0. Plasma were collected from 42 rats. Cell counts were
normalized by log transformation and analyzed using one-way ANOVA followed by Bonferroni. It should be noted the following rats did not have enough PBMCs
therefore the rat’s PBMCs reactivity were normalize to 10‘6 cells in the following rats: 2 rats from N0S0, 3 rats from N1S0 and 1 rat from N2S0. Higher cell counts were
detected in experimental group N1S3 vs. N0S0 (indicated with *, P= 0.049) and N1S0 vs. N1S3 (Indicated with#, P= 0.035). Data (except cell count) were analyzed using
Kruskal-Wallis one-way ANOVA.
doi:10.1371/journal.pone.0077799.t001
Table 2. Summary of variables collected from rats post CCI in the central region.
Variables P- value
Central (lumbar spinal cord) N0S0 N0S4 N1S3 N2S2 N4S0 N1S0 N2S0
Non-stimulated IL-1b (pg/mL) Spinal cord
supernatant
4.460.4 34.4624.9 5.160.8 9.362.9 10.465.1 16.567.5 7.361.9 0.7





5.260.6 7.161.5 6.161.4 762 661.3 9.262.7 6.761.5 0.9
Spinal cord 62612 42.662. 50.5612.2 64.4612.8 7967.2 64.8610.6 83.5613.1 0.2




6.860.7 7.762.5 11.164.6 961.8 761.3 11.865.5 6.260.8 0.9
Spinal cord 48.567.1 50.367.1 61.6610.3 81.8616.9 51.768.2 67.2611.8 66.368.9 0.6
Control Neuronal and Subcutaneous Neuronal
Experimental Groups
Data are presented as mean 6 SEM. Spinal cord sections were collected from 42 rats and stimulated with LPS at 100ug/mL and Pam3CSK4 at 100 ug/mL. Experimental
groups were analyzed using Kruskal-Wallis one-way ANOVA.
doi:10.1371/journal.pone.0077799.t002
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generated from rats and from humans to predict the presence of
pain.
Validation of Models to Predict the Presence of Pain in a
New Chronic Pain Cohort
The predict function in R was used to determine which of the
constructed models (see Figure 3 and also listed below) is the best
predictor of pain presence in the ‘‘expanded cohort’’ (all chronic
pain participants). Participant with the predicted score between 0
to 0.5 was considered to have no pain and score above 0.5 was
considered to have pain.
I. Model rat: The output variables were from the Peripheral
subset refined model obtained from rats and the data used in
this model was also from rats.
II. Model rat to human: ‘‘Model rat’’ was used however the rat
data was replaced with human data (‘‘published cohort’’).
III. Model human: Model generated from the published cohort.
Statistical Analyses
Graphpad Prism version 6.0 for Windows (GraphPad Software,
San Diego California USA, www.graphpad.com) was used for
basic statistical analysis and correlation graphs unless otherwise
stated. Data were tested for normality with the D’Agostino-
Pearson omnibus normality test and when the data did not fit
normal distribution a non-parametric test was chosen instead.
For study 1, data from the von Frey test were analyzed as the
interpolated 50% threshold (absolute threshold) in log base 10 of
stimulus intensity (monofilament stiffness in milligrams *10). The
Figure 2. The schematic representation of the breakdown of data according to anatomical location and stimulations. Experimental
groups N0S0 and N0S4 are present in both ‘‘neuronal and subcutaneous’’ (italics) and in ‘‘neuronal’’ (underline).
doi:10.1371/journal.pone.0077799.g002
Figure 3. Overview of the generation and comparison of models generated from post graded CCI rats and humans (chronic pain
and pain-free participants).
doi:10.1371/journal.pone.0077799.g003
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cell count data was normalized by log transformation. Differences
between experimental groups in von Frey score and in vitro IL-1b
post TLR agonist were analyzed using repeated measures two-way
ANOVAs followed by Bonferroni post hoc test. The experimental
groups differences on the day of cull and the cell count was
analyzed with one-way ANOVA followed by Bonferroni post hoc
test. For the other variables: plasma, basal IL-1b level, TLR
agonist stimulated IL-1b curves (min, max, slope and intercept),
TLR agonist stimulated IL-1b from spinal cord the experimental
groups differences were calculated with Kruskal-Wallis one-way
ANOVA.
For study 2, the age difference between the chronic pain
participants (published and expanded cohort) and the pain-free
participants was analyzed using one-way ANOVA. The daily
morphine used and the duration of pain between the 2 chronic
pain cohorts was analyzed using Mann-Whitney test. To
determine the group differences between the new cohort of
chronic pain patients and pain-free participants, previously
published clinical data was used [21]. The concentration-response
curve for the TLR2 agonist was assessed using a sigmoidal
concentration response equation. For the TLR4 agonist concen-
tration-response, curve a modified biphasic curve as described
previously was used [21]. The F-tests were used to determine if the
best fit curves with the selected parameters (Emax, Emin and EC50)
differed, thus reflecting group differences in the IL-1b expressed
by PBMCs post TLR agonist stimulation.
For both studies, the concentration-response curves for the
TLR2 and TLR4 agonists obtained from rats and humans were
fitted by linear regression. The minimum, maximum, slope and
intercept were calculated from the curves obtained from each rat
group, chronic pain patients and pain-free participants. All
significance was set at P,0.05.
Results
Study 1: Post Graded CCI Rat Model
Rats developed allodynia after CCI surgery. At baseline
all rats had similar behavior scores revealed by one-way ANOVA
(NS, P= 0.8) (Figure 4). After CCI surgery, two-way ANOVA
revealed a significant effects of group (P,0.0001) and time
(P,0.0001) (data not shown). On the day of cull (at least PO day
18 to PO day 27), two-way ANOVA revealed a significant group
effect was observed (P,0.0001) and Bonferroni post hoc test showed
N1S3 (P= 0.03), N2S0 (P= 0.0002), N2S2 (P= 0.0002) and N4S0
(P= 0.0002) having significantly greater allodynia when compared
to sham N0S0. The following experimental groups: N2S0
(P= 0.02), N2S2 (P= 0.02) and N4S0 (P = 0.02) were also found
to have significantly greater allodynia scores than N0S4 (no nerve
ligatures) confirming the important component of nerve involve-
ment (Figure 4).
IL-1b outputs (basal and stimulated) collected from rats
in central and peripheral regions did not differ between
Table 3. Summary of variables collected from humans in the periphery region.
Variables Published Cohort Expanded Cohort
Chronic Pain Pain-Free Chronic Pain
Non-stimulated Cell count (‘7) 1.160.09 160.12 1.260.07
Cells (pg/mL) 0.960.2 1.160.2 1263
Pam3CSK4 stimulated (TLR2) IL-1b (pg/mL) Minimum 3.562.5 2.161.1 3068.2
Maximum 929.86164.4 162.6640.5 524.5693.9
Slope 155.4633.1 31.60614.2 65.75615.4
Intercept 677.56148.3 93.4619.3 361.7669.6
LPS stimulated (TLR4) IL-1b (pg/mL) Minimum 107.6682 15.267.3 112.3637.3
Maximum 22316202.2 20086162 19756145.3
Slope 358.8640.1 289.2624.6 322.5651.1
Intercept 20656207.6 15306150.1 19306239.2
Data are presented as mean 6 SEM. Peripheral blood mononuclear cells (PBMC) were isolated from 64 participants and were stimulated with LPS (6 pg?ml21 to
10 mg?ml21) and with Pam3CSK4 (from 13 pg?ml21 to 1 mg?ml21) for 20 h.
doi:10.1371/journal.pone.0077799.t003
Figure 4. Allodynia quantification at day of cull (At least
postoperative day 18). Graded neuropathy was induced by varying
the number of chromic gut pieces ligating the nerve (N) and/or
distributed in the subcutaneous (S) compartments. The treatment
groups were N0S0, N0S4, N1S0, N1S3, N2S0, N2S2 and N4S0 (n = 6/
group). At baseline all rats responded very similarly and was not
included in the statistical analysis. A significant group effect was
observed at day of cull (P,0.0001) and with some of the experimental
groups (*P= 0.03, N0S0 vs. N1S3; **P= 0.0002, N0S0 vs. N2S0, N0S0 vs.
N2S2, N0S0 vs. N4S0; #P=0.02, N0S4 vs. N2S0, N0S4 vs. N2S2, N0S4 vs.
N4S4). Error bars on graphs represent standard error of the mean and
significance is set at P,0.05.
doi:10.1371/journal.pone.0077799.g004
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experimental groups. The basal cell level (un-stimulated) of
IL-1b expression was revealed by one-way ANOVA to be the
same for all 7 experimental groups (p = 1) (see Table 1). In contrast
to the previous human study, two-way ANOVA revealed there
were no significant group effect between all 7 experimental groups
post TLR2 (p = 0.9) or TLR4 (p= 0.1) agonist stimulation in the
isolated PBMCs but a significant concentration effects was found
for both TLR2 (p = 0.0002) and TLR4 (p = 0.001). No significant
group effect was found by the Kruskal-Wallis one-way ANOVA
for the lumbar spinal cord (Basal p = 0.8, Post TLR2 stimulated
p= 0.2 and Post TLR4 stimulated p= 0.6) or from the supernatant
(Basal p = 0.7, Post TLR2 stimulated p= 0.9 and Post TLR4
stimulated p= 0.9) showed in Table 2.
In all experimental groups Model A: Central outputs best
predicted the presence of pain in rats. The panel of output
variables that best predicted the presence of pain was from
Central region (Table 4). The area under the ROC curve (ROC
AUC) was 0.9 indicating a very good ability to determine the
presence of pain. The IL-1b released by the basal spinal cord
played a significant contribution in the model (P = 0.04). The
order of best to worse models for the predictor of pain collected
from the dataset and subsets are as follows: All.Basal.TLR2
and Peripheral.TLR4 (ROC AUC: 0.87.0.8.0.76.0. 61)
(Additional information can be found in Table S1 in File S1).
ANOVA analysis revealed the model generated from the
Complete dataset did not differ with the model collected from
the Peripheral (p = 0.09) but it was significantly different from
the models generated from output variables collected from
Central (p = 0.04), TLR2 (p = 0.02), TLR4 (p = 0.003) and
Basal (p = 0.01).
In all experimental groups Model B: A combination of all
outputs best predicted the severity of allodynia in
rats. The combined output variables (include all regions and
stimulations) that best predicted the severity of allodynia was from
All outputs (see Table 5). The actual von Frey score was
significantly correlated with the predicted von Frey score
generated from a panel of output variables (adjusted R-
square = 0.44, P= 0.0044). The following output variables played
a significant contribution to the model: TLR2 stimulated PBMC
responses (max (P = 0.01), min (P= 0.01) and intercept (P = 0.008),
basal spinal cord (P= 0.007) and TLR2 stimulated spinal cord
(P= 0.003) responses. The order of the other models generated
from the different subsets are as follows: (from best to worse
predictor of allodynia severity) Central.TLR2.Peripheral.-
Basal.TLR4 (adjusted R-square: 0.32 (P= 0.0035) .0.17
(P= 0.05) .0.17 (P= 0.11) .0.1 (NS P= 0.07) .0.0081, (NS
P= 0.37) (Additional information can be found in Table S2 in File
S1). ANOVA analysis revealed the model generated from all
outputs was significantly different from the Peripheral
(p = 0.004), TLR2 (p = 0.01), TLR4 (p = 0.003) and the Basal
(p = 0.01) subsets but it did not differ with Central (p = 0.09)
collected outputs.
In neuronal and subcutaneous experimental groups
Model A: A combination of all outputs best predicted the
presence of pain in rats. The panel of output variables that
best predicted the presence of pain was from All output variables
(Table 4). The ROC AUC was 0.9 and the order of best to worse
predictor of pain of the other models collected from the other
subsets are as follows: Peripheral and Central.TLR2.
TLR4. Basal (ROC AUC: 0.88.0.77.0.64.0.58) (Table S1
in File S1). ANOVA analysis revealed the model generated from
the All outputs variables did not differ with model collected from
Peripheral (p = 0.2), Central (p = 0.2), TLR2 (p = 0.2), TLR4
(p = 0.05) or Basal (p = 0.1).
In neuronal and subcutaneous experimental groups
Model B: TLR2 outputs best predicted the severity of
allodynia in rats. The panel of output variables that best
predicted the severity of allodynia was from TLR2 IL-1b outputs
Table 4. Best-fit logistic regression model results for the prediction of pain for rats post CCI.
Experimental




deviance df AUC ANOVA
All Central TLR4 stimulated supernatant of
spinal cord




TLR4 stimulated spinal cord 0.099 0.052 0.058
TLR2 stimulated spinal cord 0.067 0.038 0.078
Non-stimulated spinal cord 20.062 0.029 0.036
Neuronal and
subcutaneous
Complete Peripheral non-stimulated plasma 0.78 0.60 0.19 31.76 23 16.76 18 0.9 –
Peripheral non-stimulated cells 20.31 0.23 0.17











Notes: Significant variables are shown in bold. The discrimination probabilities (D, area under ROC curve) are presented in the table. One-way ANOVA was used to
compare which subsets (Central/Peripheral/TLR2/TLR4 or Basal) when compare with all outputs is a better model. The residual deviance for the model includes predictor
variables, whereas the null deviance for the model does not. SE, standard error.
doi:10.1371/journal.pone.0077799.t004
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(see Table 6). The von Frey score was significantly correlated with
the variables from the TLR2 IL-1b outputs (adjusted R-square:
0.37, P= 0.02). Within the output variables selected, the following
outputs have significant contribution: TLR2 stimulated PBMC
(max (P= 0.03), intercept (P = 0.04)) and TLR2 stimulated spinal
cord (P= 0.01). The order of the other models collected from
different dataset and subsets are as follows: (from best to worse
predictor of allodynia severity) Central .Peripheral.Basa-
l.All.TLR4 (adjusted R-square: 0.34 (P= 0.02) .0.29
(P = 0.04) .0.23 (P= 0.04) .0.56 (NS P=0.06).20.019 (NS
P=0.5) (Table S2 in File S1). ANOVA analysis revealed the
model generated from All output variables was not significantly
different from the Peripheral (p = 0.15), Central (p = 0.19),
TLR2 (p = 0.2), TLR4 (p = 0.05) and Basal (p = 0.12) specific
output variables.
In neuronal experimental groups Model A: A combination
of all outputs best predicted the presence of pain in
rats. The panel of output variables that best predicted the
presence of pain was from the All outputs variables (Table 4). The
ROC AUC was 0.86 indicating a very good ability to determine
the presence of pain. The order of the best to worse predictor of
allodynia of the other models collected from the other subsets are
as follows: Central and Basal.TLR2.Peripheral.TLR4
(ROC AUC: 0.76.0.66.0.63.0.6) (Table S1 in File S1).
ANOVA analysis revealed the outputs generated from Periph-
eral (p = 0.009) and TLR2 (p = 0.006) were significantly different
from All output variables but not with Central (p = 0.16). The
ANOVA could not be calculated for the model generated from
TLR4 output variables owing to incompatibility of the models.
In neuronal experimental groups Model B: A combination
of all outputs best predicted the severity of allodynia in
rats. The output variables that best predicted the severity of
allodynia were fromAll output variables (see Table 7). The von Frey
scorewas significantly correlatedwith the combinedoutput variables
(adjusted R-square: 0.67, P= 0.0048). Within the output variables
selected the following outputs have significant contribution: non-
stimulated cells (P = 0.001),TLR4 stimulatedPBMC(max (P= 0.02)
and slope (P = 0.03)) and TLR2 stimulated PBMC max (P= 0.02).
The orders of the othermodels collected from the other subsets are as
follows: (from best to worse predictor of allodynia severity)
Peripheral.Basal.Central.TLR2 (adjusted R-square: 0.62
(P= 0.004).0.35 (P= 0.03).0.16 (NSP=0.08).0.08 (NSP= 0.1)
(Table S2 in File S1). Correlation between von Frey score andTLR4
only outputs was not obtained due to the refined model not being
Table 5. Best-fit logistic regression model results for the prediction of the pain severity in rats post CCI in all experimental groups.







Complete Peripheral non-stimulated cell count 21.9961028 1.3061028 0.14 5.42 34 2.15 24 0.44 0.0044
Peripheral non-stimulated plasma 21.2261022 8.8461023 0.18
Peripheral TLR4 stimulated min 1.5661022 8.6961023 0.086
Peripheral TLR4 stimulated intercept 28.1361023 4.8961023 0.11
Peripheral TLR4 stimulated slope 21.3761022 6.8061023 0.055
Peripheral TLR2 stimulated max 25.2961022 1.9161022 0.011
Peripheral TLR2 stimulated min 21.2561021 4.4661022 0.0099
Peripheral TLR2 stimulated intercept 1.1961021 4.1161022 0.0078
Central TLR2 stimulated spinal cord 27.7461023 2.3261023 0.0028
Central non- stimulated spinal cord 6.3661023 2.1561023 0.0069
Spinal cord 0.0050 0.0024 0.043
Notes: Significant variables are shown in bold. The residual deviance for the model includes predictor variables, whereas the null deviance for the model does not. SE,
standard error.
doi:10.1371/journal.pone.0077799.t005
Table 6. Best-fit logistic regression model results for the prediction of the pain severity in rats post CCI in neuronal and
subcutaneous experimental groups.









Peripheral stimulated max 20.041 0.017 0.031 4.52 23 2.24 18 0.37 0.02 0.2
Peripheral stimulated min 20.073 0.058 0.23
Peripheral stimulated intercept 0.084 0.038 0.041
Central stimulated spinal cord 0.0091 0.0033 0.013
Central spinal cord supernatant 0.0046 0.0026 0.096.
Central spinal cord 0.010 0.0036 0.010
Notes: Significant variables are shown in bold. One-way ANOVA was used to compare which subsets (Central/Peripheral/TLR2/TLR4 or Basal) when compare with all
outputs is a better model. The residual deviance for the model includes predictor variables, whereas the null deviance for the model does not. SE, standard error.
doi:10.1371/journal.pone.0077799.t006
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solved. ANOVA analysis revealed the model generated from All
output variableswas significantlydifferent fromthe followingoutputs
collected in Central (p = 0.0089), TLR2 (p = 0.0063), Basal
(p = 0.022) but it was not different from the outputs collected from
Peripheral (p = 0.16).
Model C: Selected Peripheral Outputs can be Significantly
Correlated with the IL-1b from the Lumbar Spinal Cord
All experimental groups. The refined model from the
Peripheral subset correlated the best with the IL-1b released
from the basal spinal cord culture supernatant (adjusted R-square:
0.26, P= 0.003) followed by TLR4 stimulated spinal cord culture
supernatant (adjusted R-square: 0.22; P= 0.008) and lastly by
TLR2 stimulated spinal cord culture supernatant (adjusted R-
square: 0.08, P= 0.05). The same refined model was only
correlated with the TLR2 stimulated spinal cord however it did
not reach significance (adjusted R-square: 0.06, P= 0.24). Corre-
lations could not be obtained from the TLR4 stimulated spinal
cord or from the non-stimulated spinal cord.
Neuronal and subcutaneous experimental groups. The
refined model from the Peripheral subset best correlated with
the basal spinal cord culture supernatant (adjusted R-square: 0.56,
P = 0.0005) (Figure 5A) followed by TLR2 stimulated spinal cord
culture supernatant (adjusted R-square: 0.52; P= 0.01) (Figure 5C)
and lastly by TLR4 stimulated spinal cord culture supernatant
(adjusted R–square: 0.48, P= 0.02) (Figure 5E). The refined model
generated from output variables collected from Peripheral
location best correlated with the non-stimulated spinal cord
culture supernatant (adjusted R-value: 0.56, P= 0.0005)
(Figure 5B) followed by TLR2 stimulated spinal cord culture
supernatant (adjusted R-square: 0.52; P = 0.01) (Figure 5D) and
lastly TLR4 stimulated spinal cord culture supernatant (adjusted
R–square: 0.48, P = 0.02) (Figure 5F).
Study 2: Chronic Pain and Pain-free Participants
Human participant demographic data. Basic demograph-
ics are listed in Table 8. In the published cohort [21] there are
nineteen chronic pain patients (13 female, 6 male, (min-max) 33–
65 years old; mean age 52), and eleven pain-free participants (7
female, 4 male; 36–61 years old; mean age 51). In the expanded
cohort there are thirty-four chronic pain patients (25 female, 9
male, 23–64 years old, mean age 46). Additional information on
the pain diagnosis of chronic pain patients can be found in Table 9.
The average duration of pain in the published cohort was 7 years
(min-max; 1–28) and for the expanded cohort was 21 years (min –
max, 3–55). The mean daily dose (oral morphine equivalent) taken
by the published cohort was (mean 6 SEM) 49613 mg and for
the expanded cohort was 1363 mg.
Increased TLR responsiveness was observed in the
isolated PBMCs collected from the expanded cohort
compared with pain-free participants.. The TLR2 agonist
Pam3CSK4 induced significant concentration-dependent increas-
es in IL-1b release in the isolated PBMCs collected from the
chronic pain patients (expanded cohort) when compared with
pain-free participants from the previously published cohort [21].
The clear separation between the two groups resulted in an overall
significant group effect in response to Pam3CSK4 (F3, 452 = 13,
P,0.0001; see Figure 6A).
The TLR4 agonist LPS induced elevations in IL-1b in the
isolated PBMCs collected from the chronic pain patients in the
expanded cohort and in pain-free participants from the published
cohort [21]. There was a significant group difference (F1, 385 = 5,
P,0.03; see Figure 6B).
Which Model is Best at Predicting Pain Presence
Models generated from peripheral derived models from
both rats and humans have a good ability to predict
presence of pain in human. The ROC AUC generated from
the ‘‘Model rat to human’’ was 0.94 indicating a very good ability
to determine the presence of pain in humans (published cohort;
Figure 7A). Likewise, the ‘‘Model human’’ had an ROC AUC of
0.92 (Figure 7B) (Additional information of the model can be seen
in Table S3 in File S1) also indicating a very good ability to detect
the presence of pain. ANOVA analysis revealed the two models
were found to be not significantly different (Table S3 in File S1).
Model rat was found to predict presence of pain
accurately in a cohort of chronic pain participants. All
participants in the expanded cohort should be 1 (pain) however
Table 7. Best-fit logistic regression model results for the prediction of the pain severity in rats post CCI in neuronal experimental
groups.







Complete Peripheral non-stimulated plasma 20.013 0.007 0.088. 3.12 20 0.56 11 0.67 0.0048
Peripheral non-stimulated cells 0.12 0.027 0.00094
Peripheral TLR4 stimulated max 20.024 0.0089 0.022
Peripheral TLR4 stimulated slope 0.068 0.027 0.03
Peripheral TLR2 stimulated max 20.037 0.014 0.022
Central TLR4 stimulated spinal cord supernatant 20.023 0.015 0.15
Central non-stimulated spinal cord supernatant 0.013 0.0096 0.21
Central TLR2 stimulated spinal cord 20.0045 0.003 0.16
Central non-stimulated spinal cord 0.0042 0.0021 0.065.
Peripheral plasma 21.2961022 9.8961023 0.22
Peripheral cell 7.6661022 2.7961022 0.014
Central spinal cord supernatant 21.26761022 6.04161023 0.052.
Notes: Significant variables are shown in bold. The residual deviance for the model includes predictor variables, whereas the null deviance for the model does not. SE,
standard error.
doi:10.1371/journal.pone.0077799.t007
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according to all models some participants were predicted to have
no pain (Figure 8). The number of participants predicted to have
no pain/pain (from best to worst predictors) by ‘‘Model rat’’ was
6/28, for ‘‘Model rat to human’’ was 21/13 and for Model
human’’ was 14/20.
Discussion
Despite the wealth of pre-clinical evidence implicating TLR-
mediated neuroinflammation and chronic pain [9–11,26], the
relevance of neuroinflammation and TLR signaling in human
pain conditions is lacking largely due to the inaccessibility of the
CNS [3]. However, we have recently published functional
evidence of this relationship by demonstrating that low dose
intravenous endotoxin (LPS; TLR4 activator) markedly enhanced
the flare, hyperalgesia and allodynia responses to intradermal
capsaicin in healthy volunteers [27]. Despite this important
finding, this model is not practical as a pain biomarker in large
patient populations. Hence more practical biomarkers of the
neuroimmune activation status in chronic pain are needed. In this
study we have two major findings relevant to this aim. The first is
Figure 5. Rat spinal cord (basal, post TLR2 and TLR4 agonist stimulation) was positively correlated with periphery outputs. IL-1b
level released from (A) basal spinal cord supernatant (P=0.00048, adjusted R-square= 0.56) (B) basal spinal cord (P= 0.011, adjusted R-square = 0.47)
(C) spinal cord supernatant (P= 0.01, adjusted R-square = 0.52) (D) spinal cord post Pam3CSK4 (P= 0.04, adjusted R-square = 0.29) (TLR2) stimulation at
100 mg/mL (E) spinal cord supernatant (P=0.02, adjusted R-square = 0.48) (F) spinal cord (P= 0.09, adjusted R-square= 0.26) post LPS (TLR4)
stimulation at 100 mg/mL was found to be significantly correlated with the estimated values predicted from peripheral tissue outputs in rats from
Neuronal and subcutaneous. Pearson correlation was used and data shown in panel (A, E and F) have been log transformed and linear regression with
95% confidence interval curves are shown on the graph.
doi:10.1371/journal.pone.0077799.g005
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that we have replicated our earlier conclusion that in vitro PMBC
stimulation to be a biomarker of the pain state in two distinct
patient populations. Sciatica was selected as it has high face
validity to the CCI model used in our animal experiments.
Medication overuse headache was selected in contrast as there is
no evidence of peripheral pathology in this condition, yet we have
hypothesized that opioid-induced glial activation is a major
contributing pathology [28]. However cross-sectional studies
demonstrating correlation cannot demonstrate a causal relation-
ship. Hence our second major finding is that in a prospective
graded rat model we have shown that immune activation in
peripheral blood and in spinal cord were related to the pain state
in a ‘‘dose’’-related manner supporting a causal relationship.
There are two main implications of these findings. Firstly, this
confirms the likely role of TLR signaling in human chronic pain,
providing support to the search for inhibitors of these systems as
potential new treatment for pain. Secondly, excitingly, as the
sensitivity is measured in the readily accessible tissue of peripheral
blood, these assessments have the potential to act as biomarkers.
Biomarkers of pain have several potential clinical utilities. One
important potential rolewould be to support patient stratification for
Table 8. Demographic summary.







Gender (M/F) 6/13 4/7 9/25 –
Age (Years) 52 (33–65) 51 (36–61) 46 (23–64) 0.17
Oral morphine equivalent dose
(per day) (mg)
49613 – 1363 0.44
Duration of chronic pain (Years) 762 – 2162 ,0.0001
Data were collected from medical and family history. Data are expressed as mean 6 S.E.M except age is expressed as mean 6 min–max. One-way ANOVA was used to
determine the age difference and the non-parametric Mann-Whitney test was used to daily morphine dose and duration of chronic pain between the chronic pain
groups (P-values shown).
doi:10.1371/journal.pone.0077799.t008
Table 9. Primary diagnoses and medications of chronic pain














On medications other than opioids: 32 8.8
Not on medications 10 11.8
*Other pain diagnosis include: complex regional pain syndrome (n = 1), atypical
trigeminal neuralgia (n = 1), neuropathic Pain syndrome (n = 1) and non cardiac
chest pain (n = 1).
doi:10.1371/journal.pone.0077799.t009
Figure 6. TLR agonist stimulation caused significant group
differences in the release of IL-1b in chronic pain patients and
pain-free participants. Isolated white cells obtained from new
chronic pain patients (closed circle) and pain-free controls from
previous study (open triangle) were stimulated with a range of (A)
Pam3CSK4 (TLR2) concentrations (13 pg?ml21 to 1 mg?ml21) and (B)
LPS (TLR4) concentrations (6 pg?ml21 to 10 mg?ml21) to generate the
response curves and resulted in significant group differences
(Pam3CSK4; P,0.0001 and LPS, P= 0.004). Error bars on graphs
represent standard error of the mean.
doi:10.1371/journal.pone.0077799.g006
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Figure 7. Representation of ROC curves for the detection of pain presence. Models generated from (A) rat data and (B) human data
obtained from peripheral collected output variables.
doi:10.1371/journal.pone.0077799.g007
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enriched clinical trials or formonitoring the response to intervention
[29,30], making such trials more sensitive to interventions andmore
meaningful. Another potential role is in patients who cannot
communicatewell, e.g. children, patientswith cognitive impairment,
or where cultural and language barriers prevent meaningful
evaluation or comparison between populations [31].
The Superior Discrimination of Stimulated vs. Basal
Immune Responses
Our data have indicated that the innate immune responses
following TLR2 and TLR4 stimulation are both linked to the
presence of chronic pain. However, in humans, no group difference
was detected from the basal (i.e. unstimulated) cell activity. In
contrast, under stimulation conditions, discrimination between the
pain/no pain groups was possible. In rats, a combination of basal
output responses could identify the pain presence and the severity of
allodynia. However, more sensitive and specific findings were
obtained with the addition of the stimulated response. Therefore, it
is important to not only examine the basal but also dynamic
stimulation, as it allows for integrated ligand/receptor interaction,
receptor to intracellular signaling, transcriptional to translational
modification including genetic variability and epigenetic contribu-
tions. By only examining the basal response the above integration is
lost and the elicit response has proven to be important for the
discovery of potential pain biomarkers.
How has the Rodent Work Added to Our Previous
Findings?
Firstly, although cross-sectional studies in patients are easy to
perform, they suffer from the inherent weakness of potential
selection bias, and are hence at best hypothesis generating.
Prospective longitudinal studies (from pre to post injury) in
humans with neuropathic pain are difficult, as studying the
patients before the onset of injury is probably only possible in post-
surgical neuropathic pain, which is only one facet of the condition.
Since only a minority of patients experience such complications,
such studies are difficult because of very large sample sizes
required potentially and complicated by the pathology for which
Figure 8. Representation of the constructed models Model rat, Model rat to human and Model human that predicted the presence
of pain in the expanded cohort. Bin center 0 represents no pain and 1 represents pain.
doi:10.1371/journal.pone.0077799.g008
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the surgery is indicated (eg the altered immune milieu in cancer).
Hence there are several advantages of studying the neuroimmune
processes involved in pain in animals. Firstly, a study published
recently found putative pain biomarkers from blood-based RNA
transcriptome using the same preclinical graded model of pain
[32]. Many of the genes identified encode for proteins that have a
recognized role in nociceptive and immune signaling thus
providing validation for the use of this model. Secondly, animals
can be studied in a prospective manner in disease-free groups of
little heterogeneity. More importantly, CNS tissue can be accessed
directly. In this study we have shown that peripheral blood TLR
signaling sensitivity performed in a similarly predictive manner to
that from CNS-tissue sensitivity, providing construct validation to
our findings in humans. However, the discrimination of pain states
and degree of allodynia in rats was not possible on single derived
parameters from either TLR 2 or 4 stimulation, unlike in our
result in humans.
IL-1b Expression from Lumbar Spinal Cord Predicted by
Peripheral Combination Outputs
The output variables collected from peripheral sites proved to
be informative in predicting central responses. Here we demon-
strated that IL-1b expression from the rat’s lumbar spinal cord was
related to peripheral immune cell responsivity. Even though the
adjusted R-square was low, the significance of the correlation
should not be dismissed. The findings imply that samples collected
from the readily accessible peripheral circulation may provide
information as to how the CNS is responding. Thus a peripheral
marker for proinflammatory glial reactivity may be achieved
without the need to access central tissues. It is speculated that the
peripheral variables collected from chronic pain sufferers could
also predict the IL-1b expression in the central region. Further
studies are required to validate this exciting hypothesis.
The Usefulness of Neuronal and Subcutaneous
Experimental Groups
The graded CCI model allows for a better pain prediction when
chromic gut is placed both around the sciatic nerve and in the
subcutaneous space. This is supported by ROC AUC being 0.9
indicating the high accuracy to predict pain presence. The
peripheral outputs collected from the neuronal and subcutaneous
experimental groups could also be significantly correlated with
central tissue IL-1b outputs. Peripheral immune cells are known to
play a pivotal role in the establishment of chronic pain by
infiltration into central sites [33] and interact with glia causing the
release of pro-inflammatory mediators [34]. The neuronal and
subcutaneous experimental group is recommended for the
understanding of chronic pain as it better mimics the clinical
heterogeneous phenotype rather than the standard binomial
model of CCI [23].
TLR Responsiveness in the New Cohort of Chronic Pain
Patients
The level of IL-1b released from the new cohort of chronic pain
patients was not as high as previously published chronic pain
patients [21] and could be attributed the fact that the underlying
pain is very different in medication-overuse headache and sciatica
patients compared with the heterogeneous chronic pain popula-
tion employed previously. The involvement of TLR signaling with
medication-overuse headache patients is currently unknown and
has not yet been reported. It should be noted the mean daily
morphine equivalent dose of opioids in the new cohort was
significantly less even though pain was experienced longer
compared with the published cohort.
From the previous study and confirmed in the current study,
chronic pain patients have greater TLR-induced IL-1b release
from PBMCs than pain-free participants. The mechanistic cause
of the PMBC phenotype that resulted in elevated TLR-induced
IL-1b release is currently unknown. It is speculated that in chronic
pain patients PBMCs are primed by previous exposure with
DAMPs and hence following subsequent exposure to a TLR
stimulus will produce an exaggerated response (increased in IL-1b
release).
The technique of stimulating acutely isolated human PBMCs
with TLR agonists and measuring cytokines has been previously
used to examine innate immune function in patients. With the use
of this cell culture technique, differences in cell reactivity have
been detected between healthy controls and patients with the
following conditions: surgery [35], rheumatoid arthritis [36],
immunosuppression [37] and chronic fatigue syndrome [38]. This
supports the usefulness of this technique to reflect the dysregula-
tion of the immune function via the assessment of TLR signaling
efficiency. Further research is required to identify which popula-
tions of cells in chronic pain patients are responsible for this
increased IL-1b production. Using this acute isolation and
culturing approach, little time is provided to allow the cells to
differentiate away from their in vivo phenotype, thus providing
results as close to the in vivo setting as experimentally possible. We
speculate the underlying mechanisms lie in the intracellular TLR
signaling as surface TLR expression does not always correspond to
the PBMCs’ output as reported previously [37].
Models Generated from Rat Data can Predict the
Presence of Pain in Humans
The model generated from the rat was found to have very good
prediction ability for the pain presence in the new cohort of
chronic pain patients. This indicates the findings from rats could
be translated to humans. The ability of the rat model to be able to
predict the presence of pain could be attributed to more output
variables being selected. Despite the high accuracy in the
prediction of pain in chronic pain participant we do not believe
that the current biomarker is as yet a diagnostic for pain.
However, it does provide further evidence in humans of the
importance of peripheral and central reactivity and that this
biomarker approach might be useful in assessing the response to
selecting intervention for evaluation and reflecting the response for
novel treatments that target the TLR pathways. For it to be a
clinically usable biomarker it will need to fulfill additional criteria
such as discrimination between other disease states and sensitivity
to treatment responses.
Limitations of Current Study
There are several limitations in this study. Only 1 pro-
inflammatory cytokine was examined in the study as we were
testing a simplified system. As we were validating a previous
finding here we did not wish to introduce new pain mediators.
Secondly, this study only undertook collection of rat biological
samples on the day of cull. It would be informative to conduct a
longitudinal study to examine the time sequence and evolution in
the sensitivity of the output variables to predict pain. Lastly, the
same pain-free participants were used as a comparison to
investigate whether increased TLR responsiveness was also
observed with the expanded subject cohort and a larger control
group would be useful.
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Conclusions
In summary, our study is novel, in that the data-driven
approach was able to accurately predict pain presence and degree
of allodynia in rats after graded CCI surgery. The peripherally
derived model identified from rats could also be applied to humans
and allowed the prediction of pain presence with accuracy. In
addition, IL-1b levels in the central tissue could be predicted by
the peripheral outputs obtained from the rats. Collectively, these
results provide further evidence of the potential of peripheral cells
in being a source of potential pain biomarkers that can be easily
accessed and that supporting the role of TLR pathways in playing
a vital role in the understanding of chronic pain.
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